Abstract
Acquired deficiency of C1 inhibitor (C1-INH) with angioedema symptoms (acquired angioedema, AAE) is characterized by local increase in vascular permeability (agioedema) of the skin and the gastrointestinal and oro-pharyngo-laryngeal mucosa. The mediator of symptoms is bradykinin, a potent vasoactive peptide, released from high molecular weight kininogen when it is cleaved by plasma kallikrein a serine protease controlled by C1-INH. Autoantibodies inactivating C1-INH are detected in the majority of patients and account for the deficiency. Irrespectively to the presence of anti-C1-INH autoantibodies lymphoproliferative diseases, ranging from benign monoclonal gammopathies to malignant lymphoma, are frequently associated with AAE. Demonstration that monoclonal components correspond to anti-C1-INH autoantibodies and correlation between course of lymphoma and course of AAE provide strong support to consider the two diseases expression of the same pathologic process.
Keywords: Angioedema, C1 inhibitor, lymphoma, autoimmunity, vascular permeability, bradykinin, contact system
Current Molecular Medicine
Title: The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Volume: 10 Issue: 4
Author(s): M. Cicardi and A. Zanichelli
Affiliation:
Keywords: Angioedema, C1 inhibitor, lymphoma, autoimmunity, vascular permeability, bradykinin, contact system
Abstract: Acquired deficiency of C1 inhibitor (C1-INH) with angioedema symptoms (acquired angioedema, AAE) is characterized by local increase in vascular permeability (agioedema) of the skin and the gastrointestinal and oro-pharyngo-laryngeal mucosa. The mediator of symptoms is bradykinin, a potent vasoactive peptide, released from high molecular weight kininogen when it is cleaved by plasma kallikrein a serine protease controlled by C1-INH. Autoantibodies inactivating C1-INH are detected in the majority of patients and account for the deficiency. Irrespectively to the presence of anti-C1-INH autoantibodies lymphoproliferative diseases, ranging from benign monoclonal gammopathies to malignant lymphoma, are frequently associated with AAE. Demonstration that monoclonal components correspond to anti-C1-INH autoantibodies and correlation between course of lymphoma and course of AAE provide strong support to consider the two diseases expression of the same pathologic process.
Export Options
About this article
Cite this article as:
Cicardi M. and Zanichelli A., The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791317066
DOI https://dx.doi.org/10.2174/156652410791317066 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immediate Hypersensitivity Reactions to Penicillins and Other Betalactams
Current Pharmaceutical Design Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Effects of Amine Oxidases in Allergic and Histamine-Mediated Conditions
Recent Patents on Inflammation & Allergy Drug Discovery Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets Serum Sickness Reaction to Rituximab with Positive Immediate Intradermal Skin Test: A Case Report
New Emirates Medical Journal Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design Provocation Tests in Diagnosing Drug Hypersensitivity
Current Pharmaceutical Design Peptides As Therapeutics with Enhanced Bioactivity
Current Medicinal Chemistry Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry